AlphAIAlphAI — Financial news for AI agents
tradingview.com

BTIG maintains Buy rating on OrthoPediatrics, $30 price target

BTIG kept a Buy rating on OrthoPediatrics with a $30 price target, suggesting a 25.9% upside from the last close. The company reported 3Q26 revenues of $72.7M, up 18.6% YoY, and raised its FY26 revenue guidance to $270M-$273M, according to BTIG.

Original reporting
tradingview.com
Published Oct 28, 2026, 10:03 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 10:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
BTIG maintains Buy rating on OrthoPediatrics, $30 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

Med
01

Why it matters

The upgrade could trigger short-covering and new buying, supporting a price rally.

02

Market read

Analyst price target increase provides a fresh catalyst for OPK, likely prompting short-term buying.

03

What to watch

Potential execution risk on guidance and reliance on a narrow product portfolio.

Relevance 6/10Novelty 6/10Timing: pre-market today

Background

BTIG maintains a Buy rating on OPK with a $30 price target, citing strong Q3 revenue and raised FY2026 guidance.

Market effects

Sector

Positive outlook may lift other pediatric orthopedic peers.

Regional

Limited to US biotech/medical device niche.

Global

Low

Counterpoint

What could challenge this read

Target may be overly optimistic given market volatility for small caps.

Key entities

  • analyst
    BTIG

    Equity research firm issuing the rating.

  • company
    OrthoPediatrics Inc.

    Medical device company focused on pediatric orthopedics.

Read at source← All news

Related articles

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

rttnews.com
$KIDSMed

OrthoPediatrics Corp (KIDS) (Q3 2026) Earnings Call Highlights: Record Revenue and Raised Guidance

OrthoPediatrics Corp (KIDS) reported Q3 2026 revenue growth and raised guidance, despite increased sales expenses and gross margin pressure. The company expects Q4 revenue of roughly $69 million, with CEO David Bailey noting a conservative approach to guidance. International growth was tempered by Brazil headwinds, and the company remains unprofitable with a GAAP net loss per share of $0.25.

finance.yahoo.com
$KIDSMed

OrthoPediatrics Q3 Earnings Call Highlights

OrthoPediatrics (KIDS) reported Q3 revenue growth, with scoliosis revenue up 18% to $19.2M. The company surpassed 1,000 PNP tibial nail implantations and plans a full commercial release for PNP Retrograde in mid-2027. OPSB segment grew over 20%, with 60+ clinics. Gross margin remained at 74%, while GAAP net loss narrowed to $0.25 per share. The company raised full-year 2026 revenue guidance to $270M-$273M and expects positive free cash flow in 2027.

finance.yahoo.com
$KIDSHighAI 8/10

OrthoPediatrics (KIDS) Q3 2026 Earnings Call Transcript

OrthoPediatrics (KIDS) reported Q3 2026 revenue of $727M, up 19% YoY, and raised full-year guidance to $270M-$273M. Growth was driven by legacy products, implant demand, and international sales. The company highlighted progress in its innovation super cycle, with new products like 3P Hip, Traxeo, and VerteGlide contributing to performance. Adjusted EBITDA and free cash flow were record highs, with plans to maintain positive cash flow in 2027.

finance.yahoo.com